Updates
Dated notes on developments in HSV vaccine research — trial registrations, results, and status changes. A trial starting is not evidence it will succeed; each update says only what its sources support.
- State of the evidence: October 2026
A plain-language look at where herpes vaccine research stood at the end of October 2026. No tracked trial changed status this month. The two registered trials still running, for BNT163 and for an HSV-2 mRNA vaccine from Changchun BCHT, are both phase 1, small first safety tests in people. Four vaccines or vaccine approaches that have only been tested in animals were added to the tracker.
- New preclinical data extend the trivalent mRNA approach to HSV-1 eye disease
A peer-reviewed mouse study from the University of Pennsylvania group behind the trivalent gC2/gD2/gE2 mRNA design — the approach licensed to BioNTech as BNT163 — reported that the vaccine protected against HSV-1 eye infection and spread to the nervous system in mice. The findings are preclinical (in animals) and broaden the trivalent rationale beyond genital HSV-2; on their own they are not evidence of protection in people.
- Moderna ends its therapeutic HSV vaccine program (mRNA-1608)
Trade press reported on 20 November 2025 that Moderna will not advance mRNA-1608, its therapeutic HSV-2 vaccine candidate, to Phase 3, discontinuing the program as part of a company-wide pipeline cut. We have not yet confirmed this against a Moderna release or filing. Its Phase 1/2 trial had completed in April 2025 with encouraging interim data; the available reporting frames the decision as strategic rather than a reported safety or efficacy failure.
- IDWeek 2025: first clinical data for two mRNA HSV vaccine candidates
At IDWeek 2025 (19–22 October, Atlanta), interim clinical data were presented for two mRNA herpes vaccine candidates: BioNTech's prophylactic BNT163 (Phase 1) and Moderna's therapeutic mRNA-1608 (Phase 1/2). Both are early-stage safety and immune-response read-outs shared as conference abstracts — encouraging early signals, not evidence that either prevents or controls disease.